Universal Healthcare and Health Equity
The Price of the Gap
America spends more on healthcare than any peer nation—yet fails on access, equity, and outcomes. This is a document-driven exposé of the churn, consolidation, middlemen, and debt that keep “universal care” out of reach.
Thesis: The United States doesn’t lack healthcare. It lacks a system allowed to work for people instead of power—because fragmentation itself is profitable.
A door that never fully opens
The most American medical scene isn’t a surgeon in a bright operating theater. It’s a patient at a kitchen table, holding a stack of envelopes: an Explanation of Benefits that says “THIS IS NOT A BILL,” a bill that looks like a legal threat, a second bill that contradicts the first, a phone number that leads to a menu maze, and a deadline that doesn’t care whether you’re employed, grieving, postpartum, disabled, or broke.
You’re told to “advocate for yourself,” as if healthcare were a courtroom and the sick were supposed to arrive fluent in billing codes, network rules, and appeals. This is the doorway into the deeper truth: the U.S. has built a healthcare system that extracts money through fragmentation— and then calls the fragmentation “choice.”
1) The baseline indictment: pay more, get less
The OECD’s numbers are blunt: the United States spends about $14,885 per person on healthcare and roughly 17.2% of GDP, far above peer countries. That spending level would be defensible if outcomes and access were world-leading. They aren’t. International comparisons continue to rank the U.S. at or near the bottom on access, equity, administrative efficiency, and outcomes among peer nations.
2) Rationing by paperwork: churn as policy-made harm
Universal healthcare means something basic: when you get sick, you don’t first have to prove you deserve care this month. But the U.S. has perfected conditional coverage—coverage that is technically available yet constantly at risk of disappearing through administrative hurdles.
The clearest case is the post-pandemic Medicaid “unwinding.” As states resumed eligibility redeterminations after continuous coverage ended, over 25 million people were disenrolled (based on near-complete state-reported data through September 2024).
That number alone doesn’t prove every disenrolled person was eligible. It proves something more important: the U.S. repeatedly accepts a system in which coverage can be interrupted at scale—often for procedural reasons—then treats the interruption as “cost control.” Equity cannot exist inside churn. Universal anything cannot exist inside a system that expects the poor to reenroll in survival on a recurring basis.
3) Health equity isn’t a metaphor: maternal mortality
If you want a single metric that tells the truth about equity, look at maternal mortality. In 2023, the CDC reported a maternal mortality rate for Black women of 50.3 deaths per 100,000 live births, compared with 14.5 for White women and 12.4 for Hispanic women.
This is not a “lifestyle” gap. It reflects systemic failures: unequal access to high-quality obstetric care, clinical bias, fragmented coverage, postpartum care that disappears, and the geographic collapse of services where they’re least profitable. A system that can’t protect mothers equally is not merely inefficient—it is structurally unjust.
4) The administrative tollbooth: waste as an industry
America doesn’t only spend more because care costs more. America spends more because it pays armies of people to argue about who pays. A major analysis estimated U.S. insurers and providers spent about $812 billion on administration—about $2,497 per person— roughly 34.2% of national health expenditures.
That’s not a minor inefficiency. It’s a parallel economy. And complexity has beneficiaries: vendor ecosystems, contracting leverage, denial management, revenue-cycle operations, and opaque price negotiations. In a simpler universal system, some of that industry shrinks—because the point is to stop turning payment friction into a profit center.
5) Consolidation: when hospitals become pricing engines
One of the least discussed drivers of U.S. healthcare costs is market concentration: consolidation of hospitals and health systems into regional giants with negotiating power. Research using negotiated-price transparency data has found higher hospital prices in more concentrated markets, linking consolidation to pricing power.
Consolidation doesn’t only raise prices. It shapes access. It determines where clinics exist, what services are “worth it,” which neighborhoods get investment, and which communities get closures. When profitability becomes the map, equity becomes collateral.
6) Middlemen and black boxes: PBMs as a power bottleneck
Pharmacy benefit managers (PBMs) illustrate how “market solutions” can become opaque toll systems. Major analyses and congressional reporting describe a market dominated by three large PBMs—CVS Caremark, Express Scripts, and OptumRx—controlling roughly 80% of the PBM market.
Regulators and lawmakers have intensified scrutiny, including allegations that market power and incentive structures can distort drug pricing and access. Whatever your preferred reform, the equity point is unavoidable: when a handful of intermediaries control the pipes of medication access, patients become bargaining chips—especially those who can’t pay cash, can’t navigate exceptions, and can’t “shop around” while sick.
7) Medicare Advantage: “choice” that can narrow access
Medicare Advantage (MA) has become the dominant pathway for many beneficiaries. In 2025, 54% of eligible Medicare beneficiaries were enrolled in Medicare Advantage (about 34.1 million people).
But enrollment isn’t the same as access. Network design becomes a subtle form of rationing: KFF found MA enrollees were, on average, in plans that included about 48% of the physicians available to traditional Medicare beneficiaries in their area (based on 2022 network data). “Coverage” can exist while real options collapse.
8) Medical debt: the aftershock that turns illness into a financial record
In the U.S., the afterlife of illness is often debt. In January 2025, the CFPB finalized a rule intended to remove medical bills from credit reports and keep them out of credit decisions. In July 2025, a federal court vacated that rule.
Reporting on the rule described its projected impact: removing $49 billion in medical debt from credit reports for about 15 million Americans, increasing credit scores by an average of 20 points. The episode is revealing because it shows how contested even modest consumer protections remain when they threaten a pipeline that converts sickness into financial punishment.
9) The Critical Hit List: accountability questions that expose the operating logic
This is not a list of allegations. It is a list of public-interest questions that—asked repeatedly, audited, and backed by subpoena power where appropriate—clarify who benefits, who pays, and how preventable harm persists.
A) Coverage churn & Medicaid administration
- Procedural vs. true ineligibility: In each state, how many Medicaid unwinding disenrollments were for procedural reasons versus confirmed ineligibility?
- Vendor accountability: What contractors and vendors ran renewals, notices, and call centers—and what performance metrics were used to measure success or failure?
- Policy design: Which state policy choices drove higher procedural disenrollment rates (notice practices, renewal frequency, ex parte renewals, language access)?
B) Maternal mortality & hospital accountability
- Hospital-level disparities: Which systems show the worst disparities in maternal outcomes, and what documented corrective actions followed?
- Postpartum reality check: Where postpartum coverage expansions exist, are they matched by actual appointment access and high-quality care availability?
C) Administrative waste & denial culture
- Who captures the $812B: Which entities capture the largest shares of administrative spending—billing vendors, insurers, consultants, revenue-cycle operations?
- Clinician time: How much clinician time is spent on insurance-related tasks, and what patient care is displaced as a result?
D) Market power: hospitals, PBMs, vertical integration
- Consolidation and prices: Where consolidation correlates with higher negotiated prices, what antitrust actions were pursued—and why did they fail or succeed?
- Rebates vs. patients: What share of negotiated rebates and discounts reaches patients at the point of sale versus being retained inside the supply chain?
- Steering incentives: How does vertical integration (insurer + PBM + pharmacy + provider assets) reshape incentives for steering and network design?
E) Medicare Advantage: networks & forced switching
- Network adequacy: Why are MA networks frequently narrower than traditional Medicare access, and what does that do to rural and high-need patients?
- Continuity safeguards: How many enrollees are displaced by plan exits or benefit reductions—and what continuity-of-care protections actually work in practice?
F) Medical debt as a system feature
- Creditworthiness vs. sickness: Why should medical debt—often tied to opaque pricing and disputes—be allowed to shape access to housing and credit at all?
- Collections economics: Who profits from collections practices and secondary debt markets tied to medical billing?
What universal healthcare + equity would have to fix (in real terms)
Universal coverage isn’t just a coverage project. It’s an equity project, an administrative project, and a pricing project. If the U.S. ever gets serious, reforms have to be engineered around the failure modes above:
- Make coverage boringly permanent: reduce churn with automatic enrollment and simpler renewals.
- Cut administrative friction: simplify billing/payment rules and reclaim clinician time from paperwork.
- Confront market power: enforce antitrust, regulate pricing leverage, and evaluate consolidation impacts on access.
- Treat maternal equity as a system integrity test: measure and enforce standards where disparities persist.
- Build a debt firewall: stop converting illness into long-term credit and housing penalties.
- Demand supply-chain transparency: make drug pricing incentives legible and contestable.
Closing: the raw conclusion
America’s healthcare failure is often described like bad weather—tragic, complicated, nobody’s fault. But the evidence points in a harsher direction: this is a system that functions as designed for the institutions that monetize complexity, market power, and cost-shifting.
The U.S. has the money for universal care. The U.S. has clinicians. The U.S. has technology. What it does not have—yet—is a governing consensus that the purpose of healthcare is health, not extraction.
The question isn’t whether the country knows how to build a door that opens. It’s whether it will stop paying people to keep it shut.
Sources (selected, public)
Links below support the key factual claims referenced in this article.
- OECD — U.S. health spending per person and share of GDP: OECD Health at a Glance 2025 (United States)
- Commonwealth Fund — international ranking (access, equity, outcomes): Mirror, Mirror 2024
- KFF — Medicaid unwinding tracker (disenrollments): Medicaid Enrollment & Unwinding Tracker
- MACPAC — state-reported unwinding data (update brief): State-Reported Medicaid Unwinding Data Brief (PDF)
- CDC — Maternal mortality rates by race/ethnicity (2023): CDC NCHS: Maternal Mortality Rates, 2023
- Annals of Internal Medicine (via PubMed) — administrative spending estimate: U.S. vs Canada administrative costs (PubMed)
- U.S. House Oversight — PBM report (market dominance, vertical integration discussion): House Oversight PBM Report (PDF)
- KFF — Medicare Advantage enrollment (2025): Medicare Advantage Enrollment Update
- KFF — MA networks vs traditional Medicare: MA Enrollees Access to Physicians
- CFPB — medical debt rule (finalized) and subsequent updates: CFPB: Medical bills and credit reporting
